Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
23-Dec-2025 | 5,611 | 5,660 | 5,560.5 | 5,597 | 9,859 | 15,86,97,384.5 | 13,547 |
24-Dec-2025 | 5,570 | 5,593 | 5,534 | 5,566 | 6,613 | 22,93,75,604.5 | 20,989 |
26-Dec-2025 | 5,539 | 5,581 | 5,508 | 5,535 | 6,813 | 22,34,64,347.5 | 20,774 |
29-Dec-2025 | 5,573 | 5,573 | 5,481 | 5,505 | 8,499 | 21,58,59,782.5 | 20,114 |
30-Dec-2025 | 5,485 | 5,496.5 | 5,405 | 5,469 | 36,225 | 79,37,57,573.5 | 84,062 |
31-Dec-2025 | 5,450 | 5,528.5 | 5,426.5 | 5,506.5 | 9,278 | 20,60,00,038.5 | 21,750 |
01-Jan-2026 | 5,477 | 5,519.5 | 5,384 | 5,463.5 | 8,166 | 24,13,97,416 | 12,575 |
02-Jan-2026 | 5,498 | 5,600 | 5,448.5 | 5,592.5 | 8,886 | 20,90,16,313 | 20,448 |
05-Jan-2026 | 5,599 | 5,616.5 | 5,531.5 | 5,552.5 | 13,517 | 23,41,02,859.5 | 25,954 |
06-Jan-2026 | 5,554.5 | 5,679.5 | 5,554.5 | 5,655.5 | 16,042 | 48,38,48,272.5 | 48,484 |
07-Jan-2026 | 5,675 | 5,833 | 5,634.5 | 5,806.5 | 31,029 | 1,09,12,96,208 | 96,316 |
08-Jan-2026 | 5,805.5 | 5,847.5 | 5,763.5 | 5,793 | 18,024 | 77,37,59,557 | 90,229 |
09-Jan-2026 | 5,775.5 | 5,825 | 5,707 | 5,799 | 19,091 | 77,72,35,541.5 | 78,771 |
12-Jan-2026 | 5,799 | 5,886 | 5,713.5 | 5,867 | 20,236 | 68,63,87,235.5 | 69,956 |
13-Jan-2026 | 5,907 | 5,933.5 | 5,813.5 | 5,863.5 | 31,322 | 1,07,24,04,845 | 97,723 |
14-Jan-2026 | 5,888 | 5,888.5 | 5,778.5 | 5,830.5 | 18,540 | 51,86,86,751.5 | 52,539 |
16-Jan-2026 | 5,836 | 5,879.5 | 5,796.5 | 5,836.5 | 20,651 | 70,27,24,758 | 88,835 |
19-Jan-2026 | 5,835 | 5,844.5 | 5,699 | 5,748 | 22,793 | 73,84,05,382.5 | 72,760 |
20-Jan-2026 | 5,745 | 5,785 | 5,670.5 | 5,720.5 | 17,468 | 91,74,17,071.5 | 1,16,301 |
21-Jan-2026 | 5,680.5 | 5,769 | 5,586.5 | 5,656.5 | 14,261 | 43,51,62,452.5 | 28,764 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
